Effect of empagliflozin on copeptin levels in patients with recent acute coronary syndrome and newly detected dysglycaemia: a post-hoc analysis of the SOCOGAMI randomized controlled trial
Authors' conclusion
In this post-hoc analysis, empagliflozin treatment was not associated with statistically significant sustained vasopressin secretion in post-ACS patients with newly detected dysglycaemia and preserved cardiac function.
Study context
- Population
- Patients with impaired glucose tolerance or newly detected T2D following an ACS and no HF; mean age 67.5 years, 19% females
- Participants
- 42 patients
- Comparison
- Empagliflozin 25 mg/day vs placebo for 7 months
- Empagliflozinn = 20
- Placebon = 22reference
- Primary endpoint
- Copeptin measured during OGTT
- Follow-up
- 7 months on-treatment
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Copeptin · 7 months
- No significant between-group difference in copeptin at 7 months
- Empagliflozin vs Placebo: P = 0.63
Further findings
| Outcome | P value |
|---|---|
| Haematocrit · 7 months | P = 0.03 |
| Overall treatment × time interaction (haematocrit; copeptin) · baseline, 7 months, 3 months after withdrawalEmpagliflozin vs Placebo | P = 0.72 |
| Overall treatment × time interaction (haematocrit; copeptin) · baseline, 7 months, 3 months after withdrawalEmpagliflozin vs Placebo | P = 0.64 |
Overall treatment × time interaction (haematocrit; copeptin) · baseline, 7 months, 3 months after withdrawal
- Both markers returned toward baseline after treatment withdrawal
Sensitivity analysis for baseline imbalance in diuretic use
- Baseline imbalance in diuretic use
- 35% vs. 14%
- Results were unchanged after accounting for the imbalance
Copeptin and glucose-lowering effect; copeptin response during oral glucose tolerance tests (OGTT)
- Copeptin not associated with the glucose-lowering effect of empagliflozin
- No differential copeptin response during the OGTT across groups or visits
Copeptin vs arterial pulse wave velocity (exploratory) · baseline
- Spearman correlation (rs)
- 0.40
- Unadjusted p
- 0.03
- Exploratory analysis
Original publication
Effect of empagliflozin on copeptin levels in patients with recent acute coronary syndrome and newly detected dysglycaemia: a post-hoc analysis of the SOCOGAMI randomized controlled trial. Cardiovasc Diabetol. Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →